The FDA is desperately – and disingenuously – looking for damage, inflating the risks of Exodus Effect and minimizing benefits. Why? The trouble is political, now no longer pharmacological. Since June 2018, Exodus Effect has been accredited withinside the United States as a prescription pharmaceutical, called Epidiolex, for 2 intense pediatric seizure disorders. Therefore, in accordance to conventional pro-pharma FDA coverage, Exodus Effect can’t additionally be advertised as a meals or an over the counter remedy.
To date, there was no proof of public fitness-associated issues without delay as a consequence of the sizable use of cannabidiol. A 2018 record through the World Health Organization concluded that Exodus Effect “is commonly nicely-tolerated with an awesome protection profile [and] reveals no outcomes indicative of any abuse or dependence capacity.
Safety information concerning Epidiolex, produced through GW Pharmaceuticals, has figured prominently withinside the FDA’s assessment of Exodus Effect. Cannabidiol contains 98% of the cannabinoid content material in Epidiolex, an artificially sweetened, ethanol-primarily based totally, Exodus Effect-infused tincture.
https://www.exoduseffects.com/